• Please log in or register to access this feature.

SHORT REPORT

Aldehyde dehydrogenase 1 expression predicts poor prognosis in triple-negative breast cancer

  1. Yasuyo Ohi1,
  2. Yoshihisa Umekita2,
  3. Takako Yoshioka2,
  4. Masakazu Souda2,
  5. Yoshiaki Rai1,
  6. Yoshiaki Sagara1,
  7. Yasuaki Sagara1,
  8. Yoshiatsu Sagara1,
  9. Akihide Tanimoto2

Article first published online: 20 OCT 2011

DOI: 10.1111/j.1365-2559.2011.03884.x

Issue

Histopathology

Histopathology

Volume 59, Issue 4, pages 776–780, October 2011

Additional Information

How to Cite

Ohi, Y., Umekita, Y., Yoshioka, T., Souda, M., Rai, Y., Sagara, Y., Sagara, Y., Sagara, Y. and Tanimoto, A. (2011), Aldehyde dehydrogenase 1 expression predicts poor prognosis in triple-negative breast cancer. Histopathology, 59: 776–780. doi: 10.1111/j.1365-2559.2011.03884.x

Author Information

  1. 1

    Hakuaikai Sagara Hospital

  2. 2

    Department of Molecular and Cellular Pathology, Field of Oncology, Kagoshima University, Graduate School of Medical and Dental Sciences, Kagoshima, Japan

*A Tanimoto, MD, PhD, Department of Molecular and Cellular Pathology, Field of Oncology, Kagoshima University Graduate School of Medical and Dental Sciences, 8-35-1, Sakuragaoka, Kagoshima 890-8544, Japan. e-mail: akit09@m3.kufm.kagoshima-u.ac.jp

  1. Y.O. and Y.U. contributed equally to this work.

Publication History

  1. Issue published online: 20 OCT 2011
  2. Article first published online: 20 OCT 2011
  3. Date of submission 26 May 2010 Accepted for publication 23 November 2010

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (291K)

Keywords:

  • aldehyde dehydrogenase 1;
  • immunohistochemistry;
  • triple-negative breast cancer

Ohi Y, Umekita Y, Yoshioka T, Souda M, Rai Y, Sagara Y, Sagara Y, Sagara Y & Tanimoto A (2011) Histopathology59, 776–780

Aldehyde dehydrogenase 1 expression predicts poor prognosis in triple-negative breast cancer

Aims:  Aldehyde dehydrogenase 1 (ALDH1) has been identified as a reliable marker of breast cancer stem cells, and its clinical significance as a prognostic indicator of breast cancer has been reported by several investigators. However, the clinical significance of ALDH1 expression in triple-negative (TN) breast cancer, a high-risk breast cancer lacking the benefit of specific therapy, remains to be solved.

Methods and results:  We performed immunohistochemical analyses of 106 TN breast cancers, using paraffin-embedded sections. The basal-like phenotype was also investigated with the use of basal cytokeratin 5/6 and epidermal growth factor receptor. ALDH1 expression in carcinoma cells was found in 59% of cases and was correlated with high histological grade alone (P < 0.006), whereas ALDH1 expression in stromal cells was found in 49% of cases but was not correlated with any clinicopathological parameter. Patients with ALDH1 expression in carcinoma cells had a shorter relapse-free survival (RFS) according to the log-rank test (P = 0.015). According to Cox multivariate analysis, ALDH1 expression in carcinoma cells was an independent prognostic indicator of RFS (P = 0.025). The log-rank test revealed that stromal expression of ALDH1 had no effect on RFS.

Conclusions:  ALDH1 expression in carcinoma cells is an independent prognostic factor in TN breast cancer patients.

View Full Article (HTML) Get PDF (291K)